Last reviewed · How we verify

NCT03131726

Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)

Recruiting now Phase 3 Last updated 25 September 2024
What this trial tests

Phase 3 trial testing Simvastatin 40mg in Graves Ophthalmopathy in 80 participants. Currently enrolling.

Timeline
26 January 2018
Primary endpoint
26 January 2027
30 March 2028

Quick facts

Lead sponsorLund University
PhasePhase 3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment80
Start date26 January 2018
Primary completion26 January 2027
Estimated completion30 March 2028
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Lund University

Who can join

Adults 18 to 70, any sex, with Graves Ophthalmopathy or Thyroid Associated Ophthalmopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In an investigator initiated multicenter trial (Malmö, Odense, Århus) the investigators aim at evaluating activity of Graves´ophthalmopathy (GO) and progress to severe GO in patients with mild to moderate Graves´ ophthalmopathy treated with simvastatin or no treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years.
    Najjar A, Najjar A, Karaman R. · · 2020 · cited 39× · PMID 32079289 · DOI 10.3390/molecules25040884

Verify or expand the search:

Other trials of Simvastatin 40mg

Trials testing the same drug.

Other recruiting trials for Graves Ophthalmopathy

Currently open trials in the same condition.

Other Lund University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03131726.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing